Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms

Modlin IM1, Bodei L2, Kidd M3.

Best Practice & Research Clinical Endocrinology & Metabolism. 2016 January; 30(1): 59-77

This review serves to provide a general background of the evolution of NET biomarkers. It provides an assessment of their current and past usage and limitations in assessing their diagnostic, pathologic and prognostic aspects in respect of NET. It provides a view of the changing methodology of biomarker development and the application of biomathematical analyses to redefining detection and treatment. Finally, it presents a description and consensus on current advances in transcript analysis, miRNA measurement and circulating tumor cell identification.

Print Friendly, PDF & Email